Ischemic Stroke
Conditions
Keywords
fire-heat syndrome, blood stasis syndrome, method of clearing heat, method of promoting blood circulation, medicinal fractions-based herbal combinations
Brief summary
The purpose of this study is to investigate the efficacy of fractions-based herbal combinations of clearing heat and promoting blood circulation treating acute ischemic stroke and the potential mechanism of it.
Detailed description
The interaction between fire-heat and blood stasis is a significant mechanism underlying pathogenesis and progress in acute ischemic stroke according to TCM theory.Clinical therapeutic effects are achieved with wide application of Ixeris of sonchifolia Hance components (KDZ injection) representing method of clearing heat and Panax notoginseng saponins components (Xueshuantong injection) representing method of promoting blood circulation.
Interventions
KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients with acute ischemic stroke * Patients with fire-heat syndrome * Stoke onset within 48 hours * NIHSS scores range from 5 points to 25 points * Age from forty to seventy-five,gender not limited * Informed and signed the consent
Exclusion criteria
* Cardiogenic cerebral embolism,stroke caused by other reasons or the unexplained * Patients suitable for thrombolytic therapy(rt-PA, urokinase) * Patients have received thrombolytic therapy * Patients with serious diseases of heart,lungs,liver,kidneys * Patients with bleeding or bleeding tendency recently * Pregnant or lactating women * Pre-existing neurological or psychiatric diseases that could confound the study results * Patients be allergic to alcohol,Ixeris of sonchifolia Hance components (KDZ injection) or Panax notoginseng saponins components (Xueshuantong injection) * Patients have participated in other clinical trials within 3 months
Countries
China